Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100; includes inputs from SEC filing. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA yield high or low?
The EBITDA yield of 20.66% is 24% above its estimated 1-year average of 16.68%, near the high end of its estimated 1-year range (14.31%–20.66%).
As of 2026-10-06T21:17:33.699Z.
Calculation as of: 2026-10-06T21:17:33.699Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f5440d38f147f42472ad3502ccef0af83b0bc0ea844c0df361be04396bb1fdd1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
20.66%
EBITDA YIELD AVG TTM
N/A
EBITDA YIELD AVG 3Y
N/A
EBITDA YIELD AVG 5Y
N/A
EBITDA YIELD AVG 10Y
N/A
EBITDA YIELD AVG 15Y
N/A
EBITDA YIELD AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
6.35%
median of 216 covered companies
CURRENT VS SECTOR MEDIAN
+225.35%
vs the sector median at left
Market Cap
$982.46M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$973.93M
EBITDA Yield
8.78%
TTM Avg
9.22%
3Y Avg
7.66%
5Y Avg
6.32%
Market Cap
$996.65M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$998.69M
EBITDA Yield
N/A
TTM Avg
50.22%
3Y Avg
50.22%
5Y Avg
50.22%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | $981.66M | 20.66% | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.46M | N/A | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $978.09M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $973.93M | 8.78% | 9.22% | 7.66% | 6.32% |
| Vor Biopharma Inc. (VOR)vs › | $992.14M | N/A | N/A | N/A | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $996.65M | N/A | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $998.69M | N/A | 50.22% | 50.22% | 50.22% |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A | 5.69% | 5.69% | 5.69% |
| Aktis Oncology, Inc. (AKTS)vs › | $953.81M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $952.91M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA YIELD |
|---|---|
| 2026-10-05 | 19.78% |
| 2026-10-02 | 20.02% |
| 2026-10-01 | 20.27% |
| 2026-09-30 | 19.63% |
| 2026-09-29 | 19.39% |
| 2026-09-28 | 19.43% |
| 2026-09-25 | 19.79% |
| 2026-09-24 | 19.54% |
| 2026-09-23 | 18.34% |
| 2026-09-22 | 17.42% |
| 2026-09-21 | 16.43% |
| 2026-09-18 | 16.21% |
| 2026-09-17 | 16.46% |
| 2026-09-16 | 16.85% |
| 2026-09-15 | 16.85% |
| 2026-09-14 | 16.69% |
| 2026-09-11 | 16.81% |
| 2026-09-10 | 16.73% |
| 2026-09-09 | 16.20% |
| 2026-09-08 | 15.87% |
| 2026-09-04 | 15.44% |
| 2026-09-03 | 15.35% |
| 2026-09-02 | 15.25% |
| 2026-09-01 | 15.11% |
| 2026-08-31 | 15.54% |
| 2026-08-28 | 15.53% |
| 2026-08-27 | 15.17% |
| 2026-08-26 | 14.72% |
| 2026-08-25 | 14.35% |
| 2026-08-24 | 14.44% |
| 2026-08-21 | 14.95% |
| 2026-08-20 | 14.74% |
| 2026-08-19 | 14.31% |
| 2026-08-18 | 15.44% |
| 2026-08-17 | 15.58% |
| 2026-08-14 | 15.88% |
